Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 1.00 |
| ▸ | GLB1 | P16278 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 5/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GANAB | Q14697 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.46 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyfuconojirimycin SCHEMBL15686574 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876082 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL4378188 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL1867289 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL12581516 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL9999893 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13328524 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL2436650 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL15691930 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876087 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8703744-B2 | Cholesterol level lowering liposomes | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-04-22 | — | — | US | disclosed |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120237592-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | UNIVERSITY OF OXFORD | 2012-09-20 | — | — | US | disclosed |
| EP-2410989-A2 | CHOLESTEROL LEVEL LOWERING LIPOSOMES | The Chancellor, Masters and Scholars of the University of Oxford (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20090252785-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | UNIVERSITY OF OXFORD | 2009-10-08 | — | — | US | disclosed |
| WO-2009118658-A2 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | UNIVERSITY OF OXFORD (GB) | 2009-10-01 | — | — | WO | disclosed |
| EP-2054076-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | United Therapeutics Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2049126-A2 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | United Therapeutics Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2008088581-A2 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080138351-A1 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | UNITED THERAPEUTICS CORPORATION | 2008-06-05 | — | — | US | disclosed |
| WO-2008063727-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237592-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | LNPK, ERP44, ERP29 | FUCA1 1368/4885FUCA2 1102/4885GLB1 1670/4885 |
| US-20080138351-A1 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | LNPK, MAVS, DNAJA3 | FUCA1 4755/4885FUCA2 4193/4885GLB1 3671/4885 |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | FUCA1 2456/4885FUCA2 2080/4885GLB1 2225/4885 |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | GBA3, EIF2AK2, GAA | FUCA1 83/4885FUCA2 152/4885GLB1 53/4885 |
| US-20090252785-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | LNPK, ERP44, ERP29 | FUCA1 1368/4885FUCA2 1102/4885GLB1 1670/4885 |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | EIF2AK2, ZC3HAV1, HAVCR2 | FUCA1 2812/4885FUCA2 1511/4885GLB1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.